Shares of Opko Health Inc. (NASDAQ:OPK) fell 7.5% during mid-day trading on Monday . The company traded as low as $1.96 and last traded at $1.96. 8,423,713 shares were traded during trading, an increase of 67% from the average session volume of 5,056,574 shares. The stock had previously closed at $2.12.

A number of brokerages have recently issued reports on OPK. ValuEngine lowered Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Tuesday, April 30th. Finally, Barrington Research reaffirmed a “buy” rating and set a $5.00 target price on shares of Opko Health in a research report on Thursday, February 28th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Opko Health presently has an average rating of “Buy” and an average target price of $9.25.

The company has a market capitalization of $1.21 billion, a P/E ratio of -8.32 and a beta of 1.81. The company has a quick ratio of 0.99, a current ratio of 1.10 and a debt-to-equity ratio of 0.13.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.08). The firm had revenue of $222.50 million during the quarter, compared to analyst estimates of $241.27 million. Opko Health had a negative return on equity of 9.86% and a negative net margin of 19.92%. The firm’s revenue for the quarter was down 12.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.08) earnings per share. Research analysts expect that Opko Health Inc. will post -0.42 EPS for the current fiscal year.

In other news, Director Richard C. Pfenniger, Jr. purchased 50,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average cost of $2.05 per share, for a total transaction of $102,500.00. Following the completion of the purchase, the director now owns 171,310 shares of the company’s stock, valued at $351,185.50. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Phillip Md Et Al Frost purchased 20,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was purchased at an average price of $2.58 per share, with a total value of $51,600.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $7,917,893.58. The disclosure for this purchase can be found here. Insiders purchased 2,108,250 shares of company stock valued at $4,725,980 over the last quarter. Insiders own 42.25% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Piedmont Investment Advisors Inc. acquired a new position in Opko Health in the first quarter valued at approximately $27,000. Diversified Trust Co acquired a new position in Opko Health in the fourth quarter valued at approximately $30,000. FDx Advisors Inc. acquired a new position in Opko Health in the fourth quarter valued at approximately $33,000. Meeder Asset Management Inc. boosted its stake in Opko Health by 58.7% in the first quarter. Meeder Asset Management Inc. now owns 13,102 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 4,846 shares during the period. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Opko Health in the first quarter valued at approximately $39,000. Institutional investors and hedge funds own 22.64% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Opko Health (OPK) Trading Down 7.5%” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/opko-health-opk-trading-down-7-5/3011511.html.

Opko Health Company Profile (NASDAQ:OPK)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

See Also: How to interpret a stock’s beta number

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.